Document:

Exhibit 10.1

August 12, 2021

 

MedTech Acquisition Corporation 

600 Fifth Avenue, 22nd Floor

New York, NY 10022

 

Memic Innovative Surgery Ltd.

6 Yonatan Netanyahu,

Or Yehuda 6037604, Israel

 

Re: Sponsor Letter Agreement

 

Ladies and Gentlemen:

 

This letter agreement (“Sponsor
Letter Agreement”) is being delivered in accordance with that certain Business Combination Agreement (“BCA”),
dated on or about the date hereof, by and among Memic Innovative Surgery Ltd., a private company organized under the laws of the State
of Israel (the “Company”), Maestro Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary
of the Company (“Merger Sub”), and MedTech Acquisition Corporation, a Delaware corporation (“SPAC”),
pursuant to which Merger Sub will merge with and into SPAC (“Merger”), with SPAC surviving the Merger as a wholly owned
subsidiary of the Company. Capitalized terms used in this Sponsor Letter Agreement but not otherwise defined herein shall have the meanings
ascribed to such terms in the BCA.

 

In order to induce the Company
and SPAC to enter into the BCA and proceed with the Merger and in recognition of the benefit that the Merger will confer on the undersigned,
in consideration for the covenants and inducements made by the SPAC Sponsor pursuant to this Sponsor Letter Agreement, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, MedTech Acquisition Sponsor LLC, a Delaware
limited liability company (the “SPAC Sponsor”), the Company, the undersigned individuals, each of whom is a member
of SPAC’s board of directors or its management team (each, an “Insider” and collectively, the “Insiders”),
and SPAC agree to the following. Each of the SPAC Sponsor, the Company, the Insiders and SPAC are referred to herein as a “Party”
and collectively as the “Parties.”

 

1.             The
SPAC Sponsor and each Insider will (i) vote all shares of Class B common stock of SPAC, par value $0.0001 per share (“Sponsor
Shares”), and all shares of Class A common stock of SPAC, par value $0.0001 per share (“SPAC Shares”)
(including all SPAC Shares issuable upon the conversion of Sponsor Shares and all SPAC Shares underlying units of SPAC) beneficially owned
by him, her or it in favor of the Merger and each other proposal related to the Merger included on the agenda for the special meeting
of stockholders relating to the Merger, (ii) when such meeting of stockholders is held, appear at such meeting or otherwise cause
the Sponsor Shares and SPAC Shares beneficially owned by him, her or it to be counted as present thereat for the purpose of establishing
a quorum and (iii) vote all Sponsor Shares and SPAC Shares beneficially owned by him, her or it against any action that would reasonably
be expected to materially impede, interfere with, delay, postpone or adversely affect the Merger or any of the other transactions contemplated
by the BCA or result in a breach of any covenant, representation or warranty or other obligation or agreement of SPAC under the BCA or
result in a breach of any covenant or other obligation or agreement of the SPAC Sponsor or any Insider contained in this Sponsor Letter
Agreement. The obligations of the SPAC Sponsor and each Insider specified in this paragraph 1 shall apply whether or not the Merger or
any action described above is recommended by the SPAC Board (as defined in BCA).

 

     

     

    

 

2.             The
SPAC Sponsor and each Insider agrees that the Sponsor Shares and SPAC Shares beneficially owned by him, her or it may not be sold, transferred,
pledged, encumbered, assigned, hedged, swapped, converted or otherwise disposed of (collectively, “Transferred”) prior
to the Effective Time, (including by merger (including by conversion into securities or other consideration), by tendering into any tender
or exchange offer, by testamentary disposition, by operation of Law or otherwise), either voluntarily or involuntarily, and the SPAC Sponsor
and each Insider agree not to enter into any Contract or option with respect to the Transfer of any Sponsor Shares or SPAC Shares; provided,
however, that the foregoing shall not apply to any transfer (i) to SPAC’s officers or directors, any Affiliates or family
member of any of SPAC’s officers or directors, any members of SPAC Sponsor or their Affiliates, or any Affiliates of SPAC Sponsor;
(ii) by private sales or transfers made in connection with the transactions contemplated by the BCA; and (iii) by virtue of
the SPAC Sponsor’s organizational documents upon liquidation or dissolution of the SPAC Sponsor; provided, that any
transferee of any transfer of the type set forth in clauses (i) through (iii) must enter into a written agreement with the Company,
in form and substance reasonably satisfactory to the Company, agreeing to be bound by paragraphs 1-3 of this Sponsor Letter Agreement
prior to the occurrence of such transfer. Any Transfer in violation of this Section 2 with respect to the Sponsor Shares or SPAC
Shares shall be null and void.

 

3.             SPAC
Sponsor and each Insider acknowledges that he, she or it is a party to a letter agreement with SPAC dated on or about December 17,
2020 (“Existing Letter Agreement”), which includes, among other things, an agreement to vote the Sponsor Shares and
SPAC Shares in favor of a Business Combination (as defined in the Existing Letter Agreement), transfer restrictions with respect to the
Sponsor Shares and SPAC Shares, a waiver of their redemption rights with respect to shares of Capital Stock (as defined in the Existing
Letter Agreement) owned by them in connection with the consummation of a Business Combination or a stockholder vote to approve certain
amendment to the Charter (as defined in the Existing Letter Agreement), and a waiver of any and all right, title, interest or claim of
any kind in or to any monies held in the Trust Account (as defined in the Existing Letter Agreement) or any other asset of SPAC. SPAC
Sponsor and each Insider acknowledges and agrees that this Sponsor Letter Agreement is made in addition to, and does not otherwise amend,
modify, terminate, or replace, the Existing Letter Agreement.

 

4.             As
and when requested, the Company and SPAC shall deliver to the SPAC Sponsor a representation letter supporting the Intended Tax Treatment,
in substantially the form attached hereto.

 

5.             Immediately
following the consummation of the Merger, the SPAC shall contribute at least fifty percent (50%) of its total cash and liquid assets (after
taking into account the payment of the Aggregate SPAC Stockholder Redemption Payments Amount and payment of expenses incurred by the SPAC
in connection with the Merger) to Memic Inc., in exchange for such number of shares of capital stock of Memic Inc. representing an 80%
or greater interest in Memic Inc., as calculated based on the book value of such capital stock on the Closing Date. Memic Inc. shall use
the cash and other liquid assets contributed in this Section 5 to either make loans to the Company for use by the Company in its
business activities or for use by Memic Inc. in its business activities. Notwithstanding the foregoing, the SPAC shall be permitted to
make any distribution permitted under Section 6.b. below prior to the foregoing contribution.

 

    2

     

    

 

6.             During
the two-year period beginning on (and including) the Closing Date, the Company shall use reasonable best efforts to comply with the following
covenants:

 

a.            The
Company shall not cause, and shall not permit any Subsidiary of the Company to cause, SPAC to be dissolved, liquidated, or otherwise cease
to be treated as a corporation for U.S. federal income tax purposes.

 

b.            The
SPAC shall not distribute to the Company an aggregate amount greater than (i) $125,000,000, minus (ii) the Aggregate SPAC Stockholder
Redemption Payments Amount paid out of the Trust Account in connection with the Merger.

 

c.            The
Company shall not dispose of, and shall not cause or permit any member of the “qualified group” (as defined in Treasury Regulation
Section 1.368-1(d)) of the Company (the “Company Qualified Group”) to dispose of, any SPAC Shares or any shares
of capital stock of Memic Inc., other than as a result of a transfer to a member of the Company Qualified Group. For the avoidance of
doubt, the term “Company Qualified Group” includes the Company itself.

 

d.            The
aggregate value of the assets of SPAC used during such two-year period for purposes other than Permitted Uses shall not exceed the greater
of (i) fifty percent (50%) of the sum of the SPAC Cash and the Aggregate SPAC Stockholder Redemption Payments Amount, or (ii) the
Aggregate SPAC Stockholder Redemption Payments Amount. For this purpose, a “Permitted Use” is a use for one or more
of the following purposes: (1) funding investments (other than investments in debt instruments or equity instruments issued by a
member of the Company Qualified Group) or other business activities to be conducted by SPAC; or (2) transferring cash or other property
to members of the Company Qualified Group via “arm’s length” loans or equity investments for the purpose of funding
the business operations of the Company Qualified Group (provided that the interest rate under any such loans may be greater than or equal
to the Applicable Federal Rate pursuant to Internal Revenue Code Section 1274(d) and applicable Treasury Regulations applicable
to such loans and may be subject to adjustment to conform to applicable transfer pricing rules). For the avoidance of doubt, the use of
SPAC assets to (i) redeem shares of SPAC Class A Stock pursuant to the SPAC Stockholder Redemption or (ii) fund any payments,
directly or indirectly, to Company shareholders, is not a Permitted Use, and the contribution by the SPAC to Memic Inc. provided for in
Section 5 above is a Permitted Use.

 

e.            Notwithstanding
anything herein to the contrary, the Company shall notify the SPAC Sponsor in writing (in sufficient detail) prior to the use of any SPAC
Cash other than for Permitted Uses.

 

    3

     

    

 

7.             Each
Party shall use its reasonable best efforts to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take or cause
to be taken any action that prevents or impedes, or could reasonably be expected to prevent or impede, the Merger from qualifying for
the Intended Tax Treatment. Each Party shall report for all U.S. federal income tax purposes in a manner consistent with the Intended
Tax Treatment and shall not take any position inconsistent with the Intended Tax Treatment, unless otherwise required by Legal Requirements.
As of the date hereof, no Group Company is aware of any agreement or plan of a Group Company that would prevent the Merger from qualifying
for the Intended Tax Treatment. If after the date hereof and prior to the Closing Date a Group Company becomes aware of any agreement
or plan of a Group Company that would prevent the Merger from qualifying for the Intended Tax Treatment, the Company shall promptly notify
the other Parties in writing.

 

8.             The
Company and SPAC shall promptly notify SPAC Sponsor following receipt of any notice by the Company, SPAC or any of their respective Affiliates
of any Legal Proceeding initiated by any Governmental Entity in respect of, or otherwise investigating, challenging or disputing the position
that the Merger qualifies for the Intended Tax Treatment (a “Tax Claim”). Such notification shall specify in reasonable
detail the basis for such Legal Proceeding and shall include a copy of the relevant portion of any correspondence received from the applicable
Governmental Entity. To the extent any such Tax Claim relates to issues other than Section 7874, SPAC Sponsor shall have the right
to fully defend, settle or compromise any such Tax Claim at its sole cost and expense with respect to such defense, and the Company and
SPAC shall file with the applicable Governmental Entity any powers of attorney or similar authorities reasonably requested by SPAC Sponsor;
provided, however, that (i) SPAC Sponsor shall have provided the Company and SPAC with written notice electing to control
such Tax Claim within thirty (30) days after receiving written notice from the Company or SPAC of such Tax Claim, (ii) SPAC Sponsor
shall provide the Company and SPAC with a timely and reasonably detailed account of the progress of such Tax Claim, (iii) the Company
and SPAC shall have the right to attend proceedings and conferences and participate with respect to such Tax Claim, and (iv) SPAC
Sponsor shall consider in good faith any reasonable comments received in writing from the Company or SPAC prior to settling, compromising
or ceasing to defend any such Tax Claim. To the extent any Tax Claim relates solely to Section 7874, the Company and SPAC shall have
the right to fully defend, settle or compromise such Tax Claim; provided, however, that (i) the Company and SPAC shall have provided
the SPAC Sponsor with written notice of the commencement of such Tax Claim and with timely and reasonably detailed accounts of the progress
of such Tax Claim, and (ii) the Company and SPAC shall not negotiate or contest such Tax Claim in a manner that is intentionally
designed to result in a less favorable resolution with respect to any Tax Claim that relates to issues other than Section 7874. The
Company and SPAC shall not settle, compromise, appeal any adverse determination in or abandon any Tax Claim without obtaining the prior
written consent of SPAC Sponsor (which consent shall not be unreasonably withheld, conditioned or delayed). For the avoidance of doubt,
the foregoing covenants and right to control and defend shall be limited solely to the extent any Governmental Entity challenges the Intended
Tax Treatment or any item, matter or circumstance that could reasonably impact the Intended Tax Treatment (which, for the avoidance of
doubt, could be part of a more expansive Legal Proceeding), and shall not apply to any other Legal Proceeding related to Taxes of the
Company and SPAC. In the event of any Tax Claim (whether initiated at the level of the SPAC Sponsor or at the level of the Company, the
SPAC, or any of their respective Affiliates), the Company, the SPAC, and their respective Affiliates shall reasonably cooperate with SPAC
Sponsor. Such cooperation shall include the provision of records and information reasonably requested by SPAC Sponsor in connection with
such Tax Claim and making their respective employees, officers, advisors, agents, and representatives available to SPAC Sponsor on a mutually
convenient basis to provide additional information and explanation.

 

    4

     

    

 

9.             After
the Closing Date, the Company shall cause SPAC to comply with the reporting requirements contained in Treasury Regulation Section 1.367(a)-3(c)(6) unless
otherwise required by Legal Requirements.

 

10.            With
respect to each taxable year of the Company ending after the Closing Date, the Company shall use reasonable best efforts to (i) determine
if it is a “passive foreign investment company” within the meaning of Section 1297 of the Code (a “PFIC”)
for such taxable year, and (ii) make such determination within one hundred twenty (120) days after the end of such taxable year.
If the Company determines that it is a PFIC for a taxable year ending after the Closing Date, the Company shall use reasonable best efforts
to timely provide to its shareholders all information (for such taxable year and for subsequent taxable years) with respect to the Company
and its Subsidiaries that is reasonably necessary for any such shareholder (or any direct or indirect owner of such shareholder) to make
and maintain a qualified electing fund election pursuant to Section 1295 of the Code with respect to the Company (and any of its
Subsidiaries that is a PFIC).

 

11.           Effective
as of immediately prior to the conversion of the Sponsor Shares in connection with the consummation of the Transactions, the SPAC Sponsor
and the Insiders hereby irrevocably and unconditionally relinquish and waive (the “Waiver”) any and all rights that
the SPAC Sponsor or any Insider has or will have under Article Fourth, Section 4.3(b)(ii) of the SPAC’s amended and
restated certificate of incorporation (the “Charter”) to receive SPAC Shares in excess of the number issuable at the
Initial Conversion Ratio (as defined in the Charter) (the “Excess Shares”) as a result of any adjustment in connection
with the Transactions. Each of the SPAC Sponsor and each Insider agrees that, to the extent the SPAC Sponsor or such Insider receives
any Excess Shares as a result of any adjustment in connection with the Transactions, the SPAC Sponsor or such Insider, as applicable,
shall promptly return or cause the return of such shares to SPAC for cancellation. In the event the BCA is terminated in accordance with
its terms, the Waiver shall be void and of no force and effect.

 

12.           The
SPAC Sponsor hereby represents and warrants to the Company as follows:

 

a.            The
execution, delivery and performance by the SPAC Sponsor and each Insider of this Sponsor Letter Agreement and the consummation by the
SPAC Sponsor of the transactions contemplated hereby do not and will not (i) conflict with or violate any Law applicable to Sponsor,
(ii) require any consent, approval or authorization of, declaration, filing or registration with, or notice to, any person, (iii) result
in the creation of any encumbrance on any SPAC Shares (other than under this Agreement, the BCA and the agreements contemplated by the
BCA) or (iv) if applicable, conflict with or result in a breach of or constitute a default under any provision of the SPAC Sponsor’s
certificate of formation and limited liability company agreement, as amended, modified or supplemented from time to time.

 

    5

     

    

 

b.            As
of the date of this Agreement, the SPAC Sponsor and the Insiders (i) own exclusively of record and have good and valid title to 6,250,000
Sponsor Shares and zero (0) SPAC Shares (excluding, for such purposes, SPAC Shares issuable upon conversion of Sponsor Shares), free and
clear of any security interest, lien, claim, pledge, proxy, option, right of first refusal, agreement, voting restriction, limitation
on disposition, charge, adverse claim of ownership or use or other encumbrance of any kind, other than pursuant to (A) this Sponsor
Letter Agreement, (B) applicable securities Legal Requirements, and (C) SPAC’s Governing Documents, and (ii) have
the sole power (as currently in effect) to vote and right, power and authority to sell, transfer and deliver such Sponsor Shares and SPAC
Shares, and neither the SPAC Sponsor and the Insiders own, directly or indirectly, any other Sponsor Shares or SPAC Shares.

 

c.            The
SPAC Sponsor and the Insiders have the power, authority and capacity to execute, deliver and perform this Sponsor Letter Agreement and
this Sponsor Letter Agreement has been duly authorized, executed and delivered by the SPAC Sponsor.

 

13.           This
Sponsor Letter Agreement and the Existing Letter Agreement constitute the entire agreement and understanding of the Parties in respect
of the subject matter hereof and supersedes all prior understandings, agreements, or representations by or among the Parties, written
or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Sponsor Letter
Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision,
except by a written instrument executed by all Parties.

 

14.           No
Party may assign its rights or obligations under this Sponsor Letter Agreement without the prior written consent of all the other Parties.
Any purported assignment in violation of the immediately preceding sentence shall be null and void. This Sponsor Letter Agreement shall
be binding on the Parties and their permitted assigns.

 

15.           During
the period from the date of this Sponsor Letter Agreement and continuing until the earlier of the termination of this Agreement pursuant
to its terms and the Closing, neither the SPAC Sponsor nor any Insider shall, directly or indirectly: (i) solicit, initiate, knowingly
encourage (including by means of furnishing or disclosing information), discuss or negotiate, directly or indirectly, any inquiry, proposal
or offer (written or oral) with respect to a SPAC Acquisition Proposal; (ii) furnish or disclose any non-public information to any
Person in connection with a SPAC Business Combination (except that the SPAC Sponsor or any insider shall be permitted to disclose non-public
information about the Company to its limited partners, members, or shareholders of the limited purpose of securing the corporate or other
power and authority to execute and perform this Sponsor Letter Agreement, provided the SPAC Sponsor an any Insider takes reasonable efforts
to cause such Persons to comply with this Section 15); or (iv) otherwise knowingly cooperate in any way with, or knowingly
assist or participate in, or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. The SPAC
Sponsor and each Insider shall immediately cease and cause to be terminated any and all existing discussions or negotiations with any
Person with respect to any SPAC Business Combination. If the SPAC Sponsor or any Insider or any of their Affiliates receives any inquiry
or proposal regarding a SPAC Acquisition Proposal, then such SPAC Sponsor or Insider shall, to the extent legally and contractually permitted:
(A) notify the Company promptly (and in any event within twenty-four (24) hours) following receipt by such SPAC Sponsor or any Insider
of any SPAC Acquisition Proposal, and describe the material terms and conditions of any such SPAC Acquisition Proposal in reasonable
detail (including the identity of the Persons making such SPAC Acquisition Proposal) and (B) keep the Company reasonably informed
on a current basis of any modifications or other material developments with respect to such SPAC Acquisition Proposal or information.
The SPAC Sponsor and each Insider also agrees that, immediately following the execution of this Sponsor Letter Agreement, the SPAC Sponsor
and each Insider shall, and shall cause its Affiliates to, and shall use its reasonable best efforts to cause its and their respective
Representatives to, cease any solicitations, discussions or negotiations with any Person (other than the parties hereto and their respective
Representatives) conducted heretofore in connection with a SPAC Acquisition Proposal.

 

    6

     

    

 

16.           Notwithstanding
anything in this Agreement to the contrary, (i) neither of the SPAC Sponsor nor any Insider shall be responsible for the actions
of the Company or the board of directors of the Company (or any committee thereof), any Subsidiary of the Company, or any officers, directors
(in their capacity as such), other shareholders of the Company, employees and professional advisors of any of the foregoing (the “Company
Related Parties”), including with respect to any of the matters contemplated by Section 15, and (ii) neither the SPAC
Sponsor nor any Insider makes any representations or warranties with respect to the actions of any of the Company Related Parties.

 

17.            The
SPAC Sponsor and each Insider agree not to take any action that would make any representation or warranty of the SPAC Sponsor or any
Insider contained herein untrue or incorrect or have the effect of preventing or disabling the SPAC Sponsor or any Insider from performing
its obligations under this Sponsor Letter Agreement.

 

18.            The
provisions set forth in Sections 11.3 (Counterparts; Electronic Delivery), 11.5 (Severability), 11.6 (Other Remedies; Specific Performance),
11.7 (Governing Law), 11.8 (Consent to Jurisdiction; Waiver of Jury Trial), and 11.13 (Waiver), of the BCA, as in effect as of the date
hereof, are hereby incorporated by reference into, and shall be deemed to apply to, this Sponsor Letter Agreement, mutatis mutandis.

 

19.           The
representations, warranties, covenants, obligations, or other agreements in this Sponsor Letter Agreement set forth in paragraphs 1-2,
11-12 and 15-16 shall terminate on the earlier of (i) the Closing and (ii) the termination of the BCA in accordance with its
terms. Notwithstanding any provision of the BCA to the contrary, the representations, warranties, covenants, obligations, or other agreements
in this Sponsor Letter Agreement set forth in paragraphs 3-10, 13-14, and 17-18, including any rights arising out of any breach of such
representations, warranties, covenants, obligations, agreements and other provisions, shall survive the Closing; provided, further, that
this Sponsor Letter Agreement (including the representations, warranties, covenants, obligations or other agreements set forth in paragraphs
3-10, 13-14, and 17-18 of this Sponsor Letter Agreement) shall otherwise terminate, and have no further force and effect, only (A) upon
the written agreement of each of the Parties, or (B) if the BCA is terminated in accordance with its terms prior to the Closing.
In all respects, any termination of this Sponsor Letter Agreement shall not relieve the Parties from liability for any breach of this
Sponsor Letter Agreement prior to its termination. Prior to any valid termination of the BCA, the SPAC Sponsor and each Insider shall
take, or cause to be taken, all actions and do, or cause to be done, all things reasonably necessary under applicable Legal Requirements
to consummate the Merger and the other transactions contemplated by the BCA on the terms and subject to the conditions set forth therein.

 

[Signature Page Follows]

 

    7

     

    

 

IN WITNESS WHEREOF, this Sponsor Letter Agreement
has been executed as of August 12, 2021.

 

	 	 COMPANY:
	 	 
	 	  MEMIC INNOVATIVE SURGERY LTD.
	 	 
	 	By:	/s/ Dvir Cohen
	 	 	Name:  Dvir Cohen
	 	 	Title:  CEO

 

[Signature Page to
Sponsor Letter Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, this Sponsor Letter Agreement
has been executed as of August 12, 2021.

 

	 	SPAC: 
	 	 
	 	MEDTECH ACQUISITION CORPORATION
	 	 
	 	By:	/s/ Karim Karti 
	 	 	Name:  Karim Karti 
	 	 	Title:  Chairman of the Board

 

[Signature Page to
Sponsor Letter Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, this Sponsor Letter Agreement
has been executed as of August 12, 2021.

 

	 	SPONSOR: 
	 	 
	 	MEDTECH ACQUISITION SPONSOR LLC
	 	 
	 	By:	/s/ Christopher Dewey
	 	 	Name:  Christopher Dewey
	 	 	Title:  Managing Member

 

[Signature Page to
Sponsor Letter Agreement]

 

    

     

    

 

IN WITNESS WHEREOF, this Sponsor Letter Agreement
has been executed as of August 12, 2021.

 

	INSIDERS:	 
	 	 
	/s/ Karim Karti	 
	Karim Karti	 
	 	 
	/s/ Christopher Dewey	 
	Christopher C. Dewey	 
	 	 
	/s/ David J. Matlin	 
	David J. Matlin	 
	 	 
	/s/ Robert H. Weiss	 
	Robert H. Weiss	 
	 	 
	/s/ Maurice R. Ferré	 
	Maurice R. Ferré	 
	 	 
	/s/ Ivan Delevic	 
	Ivan Delevic	 
	 	 
	/s/ Martin Roche	 
	Martin Roche	 
	 	 
	/s/ Thierry Thaure	 
	Thierry Thaure	 
	 	 
	/s/ Manuel Aguero	 
	Manuel Aguero	 
	 	 
	/s/ David L. Treadwell	 
	David L. Treadwell	 

 

[Signature
Page to Sponsor Letter Agreement]Exhibit 10.2

 

Company Voting
Agreement

 

This Company Voting Agreement
(this “Agreement”) is made as of August 12, 2021, by and between MedTech Acquisition Corporation, a Delaware corporation
(“SPAC”), and the party listed on the signature page hereto as a “Shareholder” (the “Shareholder”).

 

RECITALS

 

WHEREAS, concurrently herewith,
SPAC, Memic Innovative Surgery Ltd., a private company organized under the laws of the State of Israel (the “Company”),
and Maestro Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of the Company (“Merger Sub”),
are entering into a Business Combination Agreement (as amended, supplemented, restated or otherwise modified from time to time, the “Business
Combination Agreement”). Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed
to them in the Business Combination Agreement.

 

WHEREAS, (a) immediately prior
to the Effective Time, and subject to the Company Shareholder Approval, each outstanding Company Preferred Share (including any Company
Preferred Shares issued upon exercise of the Company Preferred Warrants) will be converted into ordinary shares of the Company in accordance
with Section 2.1(a) of the Business Combination Agreement (the “Conversion”), (b) immediately following the Conversion,
all outstanding Company Ordinary Shares, and all Company Ordinary Shares underlying Vested Company Options and Company Preferred Warrants,
will be reclassified into (i) Company Ordinary Shares and (ii) Price Adjustment Rights in accordance with Section 2.1(a) of the Business
Combination Agreement (the “Reclassification”) and (c) immediately following the Reclassification, the Company will
effect a stock split of each then-outstanding Company Ordinary Share, and each Company Ordinary Share underlying any Company Options and
Company Preferred Warrants, into such number of Company Ordinary Shares calculated in accordance with Section 2.1(b) of the Business Combination
Agreement (the “Stock Split” and, together with the Conversion and the Reclassification, the “Capital Restructuring”).

 

WHEREAS, at the Effective
Time, Merger Sub shall be merged with and into SPAC (the “Merger”) with SPAC surviving the Merger as a direct wholly-owned
subsidiary of the Company.

 

WHEREAS, as of the date hereof,
the Shareholder is the record and “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange Act of
1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”)) of and is entitled
to dispose of and vote the Company Shares set forth on Schedule I hereto (collectively, the “Owned Shares”;
the Owned Shares and any additional Company Shares (or any securities convertible into or exercisable or exchangeable for Company Shares)
in which the Shareholder acquires record or beneficial ownership after the date hereof, including by purchase, as a result of a share
dividend, share split, recapitalization, combination, reclassification, exchange or change of such shares, or upon exercise or conversion
of any securities, including any Company Warrants, but specifically excluding any shares purchased by any person affiliated with the Shareholder
on account of the exercise of options, which are subject to a separate proxy, the “Covered Shares”); and

 

WHEREAS, as a condition and
inducement to the willingness of SPAC to enter into the Business Combination Agreement, SPAC and the Shareholder are entering into this
Agreement.

 

agreement

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, SPAC and the Shareholder
herby agree as follows:

 

     

     

    

 

1.                 
 Agreement to Vote. Subject to the earlier termination of this Agreement in accordance with
Section 4, the Shareholder, solely in its capacity as a shareholder of the Company, irrevocably and unconditionally agrees that
it shall, and shall cause any other holder of record of any of the Shareholder’s Covered Shares to, validly execute and deliver
to the Company a voting proxy in substantially the form attached hereto as Exhibit A (the “Voting Proxy”) in
respect of all of the Shareholder’s Covered Shares, on (or effective as of) the fifth (5th) day following the date on which the
notice of any meeting of the shareholders of the Company (the “Company Shareholders Meeting”) is delivered by the Company
(or in connection with any request for written consent of the shareholders of the Company), for the purpose of approving any of the Company
Shareholders Matters. In addition, prior to the Termination Date (as defined herein), the Shareholder, solely in its capacity as a shareholder
or proxy holder of the Company, irrevocably and unconditionally agrees that, at any Company Shareholder Meeting (whether annual or special
and whether or not adjourned or postponed and however called) and in connection with any written consent of shareholders of the Company
to approve the Company Shareholder Matters, the Shareholder shall, and shall cause any other holder of record of any of the Shareholder’s
Covered Shares to:

 

(a)               
if and when such Company Shareholders Meeting is held, appear at such meeting or otherwise cause the Shareholder’s Covered
Shares to be counted as present thereat for the purpose of establishing a quorum;

 

(b)               
execute and return an action by written consent (or vote, in person or by proxy), or validly execute and return and cause such
consent to be granted with respect to (or cause to be voted at such meeting), all of the Shareholder’s Covered Shares owned as of
the date that any written consent is executed by the Shareholder (or the record date for such meeting) in favor of (i) the Merger and
the adoption of the Business Combination Agreement, (ii) the Company Shareholder Matters, and (iii) any other matters necessary or reasonably
requested by the Company for consummation of the Merger and the other transactions contemplated by the Business Combination Agreement;
and

 

(c)               
execute and return an action by written consent (or vote, in person or by proxy), or validly execute and return and cause such
consent to be granted with respect to (or cause to be voted at such meeting), all of the Shareholder’s Covered Shares against any
Company Acquisition Proposal and any other action that would reasonably be expected to materially impede, interfere with, delay, postpone
or adversely affect the Merger or any of the other transactions contemplated by the Business Combination Agreement or result in a breach
of any covenant, representation or warranty or other obligation or agreement of the Company under the Business Combination Agreement that
would result in the failure of any condition set forth in Section 8.1, Section 8.2, or Section 8.3 of the Business Combination Agreement
to be satisfied.

 

2.                 
Proxy.

 

(a)               
The Shareholder hereby irrevocably, to the fullest extent permitted by law, appoints the Company, or any designee of the Company,
for so long as the provisions of this Section 2 remain in effect, as the Shareholder’s attorney-in-fact and proxy with full
power of substitution, to vote and otherwise act (by written consent or otherwise) with respect to the Owned Shares, solely on the matters
and in the manner specified in Section 1. The proxy shall be valid for the duration of this Agreement.

 

(b)                THE
PROXIES AND POWERS OF ATTORNEY GRANTED PURSUANT TO SECTION 2(b) ARE IRREVOCABLE AND COUPLED WITH AN INTEREST. The proxies and
powers of attorney shall not be terminated by any act of the Shareholder or by operation of law, by lack of appropriate power or
authority, or by the occurrence of any other event or events and shall be binding upon all successors, assigns, heirs, beneficiaries
and legal representatives of the Shareholder. The Shareholder hereby revokes all other proxies and powers of attorney on the matters
specified in Section 1 with respect to the Owned Shares
that the Shareholder may have previously appointed or granted, and no subsequent proxy or power of attorney shall be given or
written consent executed (and if given or executed, shall not be effective) by the Shareholder with respect thereto. All authority
herein conferred or agreed to be conferred shall survive the death, bankruptcy or incapacity of the Shareholder and any obligation
of the Shareholder under this Agreement shall be binding upon the heirs, personal representatives, and successors of the
Shareholder. 

 

     

     

    

 

3.                 
No Inconsistent Agreements. The Shareholder hereby covenants and agrees that the Shareholder
shall not, at any time prior to the Termination Date, (i) enter into any voting agreement or voting trust with respect to any of the Shareholder’s
Covered Shares that is inconsistent with the Shareholder’s obligations pursuant to this Agreement, (ii) grant a proxy or power of
attorney with respect to any of the Shareholder’s Covered Shares that is inconsistent with the Shareholder’s obligations pursuant
to this Agreement, or (iii) enter into any agreement or undertaking that is otherwise inconsistent with, or would interfere with, or prohibit
or prevent it from satisfying, its obligations pursuant to this Agreement.

 

4.                 
Termination. This Agreement shall terminate, and no party shall have any further obligations
or liabilities under this Agreement, upon the earliest of (i) the Effective Time, (ii) the termination or expiration of the Business Combination
Agreement in accordance with its terms, or (iii) the time this Agreement is terminated upon the mutual written agreement of SPAC and the
Shareholder (the earliest such date under clause (i), (ii) and (iii) being referred to herein as the “Termination Date”);
provided that the provisions set forth in Sections 10 and 21 below shall survive the termination of this Agreement;
provided further that the termination of this Agreement shall not relieve any party hereto from any liability for any Willful Breach
of, or actual fraud in connection with, this Agreement prior to such termination.

 

5.                 
Representations and Warranties of the Shareholder. The Shareholder hereby represents and warrants
to SPAC as to itself as follows: 

 

(a)               
Ownership of Shares. The Shareholder is the only record and beneficial owner (within the meaning of Rule 13d-3 under the
Exchange Act) of, and has good, valid and marketable title to, the Covered Shares, free and clear of Liens that may impede such Shareholder
from complying with its obligations hereunder other than as created by this Agreement and Permitted Liens. As of the date hereof, other
than the Owned Shares, the Shareholder does not own beneficially or of record any share capital of the Company (or any securities convertible
into share capital of the Company).

 

(b)               
Voting Rights. The Shareholder (i) except as provided in this Agreement, has full voting power, full power of disposition
and full power to issue instructions with respect to the matters set forth herein, in each case, with respect to the Shareholder’s
Covered Shares, (ii) has not entered into any voting agreement or voting trust with respect to any of the Shareholder’s Covered
Shares that is inconsistent with the Shareholder’s obligations pursuant to this Agreement and (iii) has not granted a proxy or power
of attorney with respect to any of the Shareholder’s Covered Shares that is inconsistent with the Shareholder’s obligations
pursuant to this Agreement.

 

(c)                Authority. If
the Shareholder is an entity, such Shareholder has the power and authority and all authorization and approval required by law to
enter into, deliver and perform its obligations under this Agreement with respect to its Covered Shares. If such Shareholder is an
individual, such Shareholder has the capacity, full legal right, power and authority and all authorization and approval required by
law to enter into, deliver and perform its obligations under this Agreement with respect to its Covered Shares. This Agreement has
been duly authorized, executed and delivered by the Shareholder and, assuming that this Agreement constitutes a valid and binding
obligation of the other parties hereto, is enforceable against such Shareholder in accordance with its terms, subject to the
Enforcement Exceptions.

 

     

     

    

 

(d)               
No Consent. Other than the filings, notices and reports pursuant to, in compliance with or required to be made under the
Exchange Act, if any, no filings, designations, declarations, notices, reports, consents, registrations, approvals, permits, waivers,
expirations of waiting periods or authorizations are required to be obtained by the Shareholder from, or to be given by the Shareholder
to, or be made by the Shareholder with, any Governmental Entity or other Person in connection with the execution, delivery and performance
by the Shareholder of this Agreement, other than any such filings, designations, declarations, notices, reports, consents, registrations,
approvals, permits, waivers, expirations of waiting periods or authorizations which have been previously obtained or expired, as applicable.
If the Shareholder is a natural person, no consent of such Shareholder’s spouse or creditor is necessary under any “community
property” or other laws for the execution and delivery of this Agreement.

 

(e)               
No Conflicts. The execution, delivery and performance of this Agreement by the Shareholder do not, and the consummation
of the transactions contemplated hereby will not, constitute or result in (i) a breach or violation of, or a default under, the limited
liability company agreement or similar governing documents of the Shareholder, if the Shareholder is an entity, (ii) with or without notice,
lapse of time or both, a breach or violation of, a termination (or right of termination) of or a default under, the loss of any benefit
under, the creation, modification or acceleration of any obligations under or the creation of a Lien on any of the properties, rights
or assets of the Shareholder pursuant to any Contract binding upon the Shareholder or, assuming (solely with respect to performance of
this Agreement and the transactions contemplated hereby), compliance with the matters referred to in Section 5(d), under any applicable
Law to which the Shareholder is subject or (iii) any change in the rights or obligations of any party under any Contract legally binding
upon the Shareholder, except, in the case of clause (ii) or (iii) directly above, for any such breach, violation, termination, default,
creation, acceleration or change that would not, individually or in the aggregate, reasonably be expected to prevent or materially delay
or impair the Shareholder’s ability to perform its obligations hereunder or to consummate the transactions contemplated hereby.

 

(f)                
No Litigation. As of the date of this Agreement, there is no action, proceeding or investigation pending against the Shareholder
or, to the knowledge of the Shareholder (after conducting reasonable and due inquiry), threatened against the Shareholder that questions
the beneficial or record ownership of the Shareholder’s Owned Shares.

 

(g)               
Reliance upon Agreement. The Shareholder understands and acknowledges that SPAC and the Company are entering into the Business
Combination Agreement in reliance upon the Shareholder’s execution and delivery of this Agreement and the representations, warranties,
covenants and other agreements of the Shareholder contained herein.

 

6.                 
Certain Covenants of the Shareholder. 

 

(a)                Subject
to Section 7 hereof, prior to the Termination Date, the Shareholder shall not, and shall cause its Affiliates and
Subsidiaries not to, and shall not authorize its Representatives to, and shall use its reasonable best efforts to cause its and
their respective Representatives not to, directly or indirectly, (i) solicit, initiate, knowingly encourage or knowingly facilitate
(including by means of furnishing or disclosing information, subject to the exception set forth in clause (ii) below), discuss or
negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) that constitutes, or may reasonably be expected
to result in or lead to a Company Acquisition Proposal; (ii) furnish or disclose any non-public information about the Company to any
Person that would reasonably be expected to lead to a Company Acquisition Proposal (except that the Shareholder shall be permitted
to disclose non-public information about the Company to its limited partners, members, or shareholders for the limited purpose of
securing the corporate or other power and authority to execute and perform this Agreement, provided the Shareholder takes reasonable
efforts to cause such Persons to comply with this Section 6(a));
(iii) enter into any Contract or other arrangement or understanding regarding a Company Acquisition Proposal; or (iv) otherwise
knowingly cooperate in any way with, or knowingly assist or participate in, or knowingly facilitate or encourage any effort or
attempt by any Person to do or seek to do any of the foregoing. If the Shareholder or any of its Affiliates receives any inquiry or
proposal regarding a Company Acquisition Proposal, then the Shareholder shall: (A) notify the Company promptly (and in any event
within twenty-four (24) hours) following receipt by the Shareholder of any Company Acquisition Proposal, and describe the material
terms and conditions of any such Company Acquisition Proposal in reasonable detail (including the identity of the Persons making
such Company Acquisition Proposal) and (B) keep the Company reasonably informed on a current basis of any modifications or other
material developments with respect to such Company Acquisition Proposal or information. The Shareholder also agrees that,
immediately following the execution of this Agreement, the Shareholder shall, and shall cause its Affiliates and Subsidiaries to,
and shall use its reasonable best efforts to cause its and their respective Representatives to, cease any solicitations, discussions
or negotiations with any Person (other than the parties hereto and their respective Representatives) conducted heretofore in
connection with a Company Acquisition Proposal.

 

     

     

    

 

Notwithstanding
anything in this Agreement to the contrary, (i) the Shareholder shall not be responsible for the actions of the Company or the board of
directors of the Company (or any committee thereof), any Subsidiary of the Company, or any officers, directors (in their capacity as such),
other shareholders of the Company, employees and professional advisors of any of the foregoing (the “Company Related Parties”),
including with respect to any of the matters contemplated by this Section 6(a), (ii) the Shareholder makes no representations or
warranties with respect to the actions of any of the Company Related Parties and (iii) any breach by the Company of its obligations under
Section 7.10 (No Solicitation) of the Business Combination Agreement shall not be considered a breach of this Section 6(a)
(it being understood for the avoidance of doubt that the Shareholder shall remain responsible for any breach by the Shareholder or its,
his or her Representatives (other than any such Representative that is a Company Related Party) of this Section 6(a)).

 

(b)               
The Shareholder hereby agrees not to, directly or indirectly, prior to the Termination Date, except in connection with the consummation
of the Transactions, (i) sell, transfer, pledge, encumber, assign, hedge, swap, convert or otherwise dispose of (including by merger (including
by conversion into securities or other consideration), by tendering into any tender or exchange offer, by testamentary disposition, by
operation of Law or otherwise), either voluntarily or involuntarily (collectively, “Transfer”), or enter into any Contract
or option with respect to the Transfer of any of the Shareholder’s Covered Shares, or (ii) take any action that would make any representation
or warranty of the Shareholder contained herein untrue or incorrect or have the effect of preventing or disabling the Shareholder from
performing its obligations under this Agreement; provided, however, that nothing herein shall prohibit a Transfer to an Affiliate,
equityholder or Permitted Transferee (as defined in the Company’s Articles of Association in effect on the eve of signing the Business
Combination Agreement) of the Shareholder (a “Permitted Transfer”); provided, further, that any Permitted
Transfer shall be permitted only if, as a precondition to such Transfer, the transferee agrees in a writing, reasonably satisfactory in
form and substance to SPAC, to assume all of the obligations of the Shareholder under, and be bound by all of the terms of, this Agreement;
provided, further, that any Transfer permitted under this Section 6(b) shall not relieve the Shareholder of its obligations
under this Agreement. Any Transfer in violation of this Section 6(b) with respect to the Shareholder’s Covered Shares shall
be null and void.

 

7.                 
 Termination of Investors’ Rights Agreement. The Shareholder, by this Agreement, with
respect to its Covered Shares, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the Effective
Time, the Investors’ Rights Agreement.

 

     

     

    

 

8.                 
Disclosure. The Shareholder hereby authorizes the Company and SPAC to publish and disclose
in any announcement or disclosure required by the SEC, or include in any document or information required to be filed with or furnished
to the SEC or NASDAQ, the Shareholder’s identity and ownership of the Covered Shares and the nature of the Shareholder’s obligations
under this Agreement; provided that prior to any such publication or disclosure, the Company and SPAC have provided the Shareholder
with an opportunity to review and comment upon such announcement or disclosure, which comments the Company and SPAC will consider in good
faith.

 

9.                 
Changes in Share Capital. In the event of a share split, share dividend or distribution, or
any change in the Company’s share capital by reason of any split-up, reverse share split, recapitalization, combination, reclassification,
exchange of shares or the like, the terms “Owned Shares” and “Covered Shares” shall be deemed to refer to and
include such shares as well as all such share dividends and distributions and any securities into which or for which any or all of such
shares may be changed or exchanged or which are received in such transaction.

 

10.             
Amendment and Modification. This Agreement may not be amended, modified or supplemented in
any manner, whether by course of conduct or otherwise, except by an instrument in writing signed by SPAC and the Shareholder.

 

11.             
Waiver. Any party to this Agreement may, at any time prior to the Termination Date, waive
any of the terms or conditions of this Agreement or agree to an amendment or modification to this Agreement in the manner contemplated
by Section 10 and by an agreement in writing executed in the same manner (but not necessarily by the same Persons) as this Agreement.

 

12.             
Notices. All notices and other communications hereunder shall be in writing and shall be deemed
given: (a) on the date of delivery if delivered personally; (b) one (1) Business Day after being sent by a nationally recognized
overnight courier guaranteeing overnight delivery; (c) when sent, if delivered by email (provided that no “error message”
or other notification of non-delivery is generated); or (d) on the fifth (5th) Business Day after the date mailed, by certified or
registered mail, return receipt requested, postage prepaid. Such communications, to be valid, must be addressed as follows:

 

	
    if to SPAC, to:

     
	 
	 	
    c/o SPAC

    MedTech Acquisition Corporation

    600 Fifth Avenue, 22nd Floor

    New York, NY 10022

    Attention:          Christopher C. Dewey

    Email:                ccdewey@gmail.com

     

	
    with a copy to (which shall not constitute notice):

     

	 	
    Foley & Lardner LLP

    100 N Tampa St Suite 2700

    Tampa, FL 33602

    Attention:         Kevin Shuler

    Phone:              813.225.5441

    Email:               kshuler@foley.com

     

     

     

    

 

	
    and

     
	 
	 	
    Meitar | Law Offices

    16 Abba Hillel Rd.

    Ramat Gan 5250608, Israel

    Attention: Clifford M.J. Felig

    Phone: +972-3-610-3100

    Email: cfelig@meitar.com  

	 

If to the Shareholder, to such address indicated
on the Company’s records with respect to the Shareholder to such other address or addresses as Shareholder may from time to time
designate in writing.

 

13.             
No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in SPAC
any direct or indirect ownership or incidence of ownership of or with respect to the Covered Shares of the Shareholder. All rights, ownership
and economic benefits of and relating to the Covered Shares of the Shareholder shall remain vested in and belong to the Shareholder, and
SPAC shall have no authority to manage, direct, restrict, regulate, govern or administer any of the policies or operations of the Company
or exercise any power or authority to direct the Shareholder in the voting or disposition of any of the Shareholder’s Covered Shares,
except as otherwise provided herein.

 

14.             
Entire Agreement. This Agreement and the Business Combination Agreement constitute the entire
agreement among the parties hereto with respect to the subject matter hereof and supersede all other prior agreements and understandings,
both written and oral, among the parties hereto with respect to the subject matter hereof. No representations, warranties, covenants,
understandings or agreements, oral or otherwise, with respect to the subject matter contemplated by this Agreement exist between the parties
hereto except as expressly set forth or referenced in this Agreement and the Business Combination Agreement. In the event of any inconsistency,
conflict, or ambiguity as to the rights and obligations of the parties hereto under this Agreement and the Business Combination Agreement,
the terms of this Agreement shall control and supersede any such inconsistency, conflict or ambiguity.

 

15.             
Miscellaneous.The provisions set forth in Sections 11.3 (Counterparts; Electronic Delivery),
11.5 (Severability), 11.6 (Other Remedies; Specific Performance), 11.7 (Governing Law), 11.8 (Consent to Jurisdiction; Waiver of Jury
Trial), and 11.13 (Waiver), of the Business Combination Agreement, as in effect as of the date hereof, are hereby incorporated by reference
into, and shall be deemed to apply to, this Agreement, mutatis mutandis. 

 

16.             
Non-Recourse. This Agreement may only be enforced against, and any claim or cause of action
based upon, arising out of, or related to this Agreement or the transactions contemplated hereby may only be brought against, the entities
that are expressly named as parties hereto, and then only with respect to the specific obligations set forth herein with respect to such
party. Except to the extent a named party to this Agreement (and then only to the extent of the specific obligations undertaken by such
named party in this Agreement), (a) no past, present or future director, officer, employee, incorporator, member, partner, shareholder,
affiliate, agent, attorney, advisor or representative or affiliate of any named party to this Agreement and (b) no past, present or future
director, officer, employee, incorporator, member, partner, shareholder, affiliate, agent, attorney, advisor or representative or affiliate
of any of the foregoing shall have any liability (whether in contract, tort, equity or otherwise) for any one or more of the representations,
warranties, covenants, agreements or other obligations or liabilities of any one or more of SPAC, the Company or the Shareholder under
this Agreement of or for any claim based on, arising out of, or related to this Agreement or the transactions contemplated hereby.

 

     

     

    

 

17.             
 Assignment; Successors; No Third Party Rights. Other than Permitted Transfers by the Shareholder
pursuant to Section 6(b), and then only on the terms therein, no party hereto may assign, directly or indirectly, including by
operation of law, either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of
the other parties. Subject to the foregoing sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon
any other Person (other than the Company, which shall be an intended beneficiary of the provisions hereof) any legal or equitable right,
benefit or remedy of any nature whatsoever under or by reason of this Agreement. Any purported assignment or delegation made in violation
of this provision shall be void and of no force or effect.

 

18.             
Interpretation and Construction. The words “hereof,” “herein” and
 “hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular
provision of this Agreement. The descriptive headings used herein are inserted for convenience of reference only and are not intended
to be part of or to affect the meaning or interpretation of this Agreement. References to Sections are to Sections of this Agreement unless
otherwise specified. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. The
definitions contained in this Agreement are applicable to the masculine as well as to the feminine and neuter genders of such term. Whenever
the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to
be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like import.
 “Writing,” “written” and comparable terms refer to printing, typing and other means of reproducing words (including
electronic media) in a visible form. References to any statute shall be deemed to refer to such statute and to any rules or regulations
promulgated thereunder. References to any person include the successors and permitted assigns of that person in accordance with the terms
of this Agreement. References from or through any date mean, unless otherwise specified, from and including such date or through and including
such date, respectively. In the event an ambiguity or question of intent or interpretation arises, this Agreement will be construed as
if drafted jointly by the parties, and no presumption or burden of proof will arise favoring or disfavoring any party by virtue of the
authorship of any of the provisions of this Agreement.

 

19.             
Severability. In the event that any term, provision, covenant or restriction of this Agreement,
or the application thereof, is held to be illegal, invalid or unenforceable under any present or future Legal Requirement: (i) such provision
will be fully severable; (ii) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had
never comprised a part hereof; (iii) the remaining provisions of this Agreement will remain in full force and effect and will not be affected
by the illegal, invalid or unenforceable provision or by its severance herefrom; and (iv) in lieu of such illegal, invalid or unenforceable
provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms
of such illegal, invalid or unenforceable provision as may be possible.

 

20.             
Counterparts. This Agreement may be executed in multiple counterparts, all of which shall
be considered one and the same document and shall become effective when multiple counterparts have been signed by each of the parties
and delivered to the other parties, it being understood that all parties hereto need not sign the same counterpart. Delivery by electronic
transmission to counsel for the other parties of a counterpart executed by a party shall be deemed to meet the requirements of the previous
sentence.

 

21.              Capacity
as a Shareholder. Notwithstanding anything herein to the contrary, the Shareholder signs this Agreement solely in the
Shareholder’s capacity as a shareholder or proxy holder of the Company, and not in any other capacity and this Agreement shall
not limit or otherwise affect the actions of any affiliate, employee or designee of the Shareholder or any of its affiliates in his
or her capacity, if applicable, as an officer or director of the Company or any other Person. The Shareholder shall not be liable or
responsible for any breach, default, or violation of any representation, warranty, covenant or agreement hereunder by any
other shareholder that is entering into a similar Agreement and the Shareholder shall solely be required to perform its obligations
hereunder in his, her or its individual capacity.

 

[Remainder of Page Intentionally Left Blank]

 

     

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed (where applicable, by their respective officers or authorized Persons thereunto duly
authorized) as of the date first written above.

 

	 	
    MEDTECH ACQUISITION CORPORATION

	 	 
	 	By:	                          
	 	Name:  Karim Karti
	 	Title:   Chairman of the Board
	 	 

     

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed (where applicable, by their respective officers or authorized Persons thereunto duly
authorized) as of the date first written above.

 

	 	[COMPANY SHAREHOLDER]
	 	 
	 	By:	                         
	 	Name:  
	 	Title:  

     

     

    

 

SCHEDULE I

 

Owned Shares

 

The Shareholder is the record and “beneficial
owner” (within the meaning of Rule 13d-3 under the Exchange Act) of and is entitled to dispose of and vote the following Company
Shares:

 

	 	Company Ordinary Shares 
	 	Company Preferred A Shares 
	 	Company Preferred A-1 Shares
	 	Company Preferred B Shares
	 	Company Preferred C-1 Shares
	 	Company Preferred C-2 Shares 
	 	Company Preferred D-1 Shares
	 	Company Preferred D-2 Shares
	 	Company Preferred D-3 Shares
	 	Company Preferred D-4 Shares
	 	Company Preferred D-5 Shares 

 

     

     

    

 

EXHIBIT A 

Proxy 

 

 

 

[Attached].

 

     

     

    

 

MEMIC INNOVATIVE SURGERY LTD.

 

NOTICE OF A SPECIAL GENERAL MEETING OF THE SHAREHOLDERS
TO BE HELD

 

_______ __, 2021

 

Notice is hereby given that
a Special General Meeting (the “Meeting”) of the shareholders (the “Shareholders”) of Memic Innovative
Surgery Ltd. (the “Company”) will be held at the offices of the Company, located at 6 Yonatan Netanyahu, Or Yehuda
6037604, Israel on ____ __, 2021 at 4:00 p.m., Israel time and also via zoom at the following link: __________________. This Notice is
being emailed to the Shareholders on August __, 2021 (the “Notice”).

 

Capitalized terms used and not otherwise defined
herein, shall have the respective meanings ascribed to them under this Notice or under the Business Combination Agreement (as defined
below)

 

The Meeting is being called
for the following purposes

 

		1.	To authorize and approve the execution, delivery and performance of the Business Combination Agreement,
dated as of August 12, 2021 (the “Business Combination Agreement”), by and among the Company, MedTech Acquisition Corporation,
a Delaware corporation (“SPAC”), and Maestro Merger Sub, Inc., a Delaware corporation (“Merger Sub”),
in the form attached hereto as Exhibit A, and the Transactions, including the Reclassification, the Merger and issuance
of the Price Adjustment Rights in the Reclassification, as well as all of the Transaction Agreements to which the Company is a party and
the termination of the Company’s Investors Rights Agreement.

 

		2.	To approve and adopt the Company’s 2021 Incentive Compensation Plan, in the form attached hereto
as Exhibit B, as well as the Sub-Plan for Israeli taxpayers in the form attached hereto as Exhibit C (collectively,
the “Equity Plan”) and to authorize the reserve for issuance under the Equity Plan a number of Company Ordinary Shares
equal to 15% of the total number of issued and outstanding Company Ordinary Shares on a fully diluted and as converted basis immediately
following the Closing.

 

		3.	To authorize and approve, contingent upon the Closing, the classification of the Company’s share
capital by (A) converting all of the Company Preferred Shares (including the Company Preferred Shares issued or issuable upon exercise
of Company Warrants) into Company Ordinary Shares (with the voting for such resolution (whether in person or by proxy) will constitute
a written demand of all such holders of Company Preferred Shares) in accordance with the conversion ratios determined pursuant to the
Current Company Articles and (B) effect a share split of each Company Ordinary Share, and each Company Ordinary Share underlying any Company
Options and Company Warrants shall become [__] Company Ordinary Shares par value ILS [__] each, such that following such classification,
the Company’s authorized share capital shall be ILS [__] divided into [__] Company Ordinary Shares, par value ILS [__] each.

 

		4.	To authorize and approve, contingent upon the Closing, that the Price Adjustment Rights, the Merger Consideration,
the Company Warrants and the Company Ordinary Shares issuable upon exercise of any of the above, will be exempt and excluded from the
definition of Additional Shares (as such term is defined in the Current Company Articles).

 

		5.	To replace the Current Company Articles in their entirety with the Company A&R Articles, in the form
attached hereto as Exhibit D, contingent upon the Closing.

 

		6.	To approve the form of indemnification agreement, substantially in the form attached hereto as Exhibit
E (the “Indemnification Agreement”), and to authorize and approve the execution, delivery and performance of
such Indemnification Agreement with each director and officer of the Company, at present or in the future.

 

     

     

    

 

		7.	To approve, contingent upon the Closing, that the following individuals be elected (or re-elected, as
applicable) as members of the Board of Directors of the Company (the “Board”), effective as of the Closing: [________],
such that as of the Closing, the Board shall consist of the following directors: [_______].

 

		8.	To approve and confirm (A) the capitalization table attached hereto as Exhibit F, as being
the complete, correct and accurate capitalization table of the Company effective as of July 31, 2021, which reflects details of the Company’s
share capital as of such time, and (B) the shareholders register attached hereto as Exhibit G, as being the complete, correct
and accurate register of shareholders of the Company effective as of July 31, 2021, which reflects the details of all shares of the Company
outstanding as of such time. To approve any and all issuances of shares of the Company, any and all grants of warrants to purchase shares
or other securities of the Company (and, if applicable, the exercise thereof and the issuance of shares upon such exercise), any and all
transfers of shares of the Company, and any and all other actions previously made in, or with respect to, the share capital of the Company,
in each case, which have been consummated prior to the date hereof and that eventually resulted in the holdings of securities of the Company
as specified in and contemplated by Exhibit F and Exhibit G attached hereto (in each case, if and when made, and only to the extent not
previously approved or ratified), be ratified and approved in all respects effective as of the respective dates of such issuance, grant,
exercise, transfer or other action, as applicable, and that the issuance of the applicable shares of the Company upon the exercise of
each warrant or other security or right specified in Exhibit F attached hereto, if and when exercised in accordance with its respective
terms, shall be ratified and approved in all respects.

 

Please execute the attached
proxy for the above resolution, sign the signature page of the proxy at your earliest convenience, return the executed proxy to Noam Atar
via e-mail at noam@memicmed.com. If the attached proxy is properly executed and returned, and a choice is specified, the shares represented
thereby will be voted as indicated thereon. If no specification is made, the proxy will be voted in favor of such proposal. Proxies must
be received prior to the scheduled time of the Meeting in order for the proxy to be qualified to participate in the Meeting.

 

Please note that the information
contained in this notice, its exhibits and the attached proxy is confidential and is intended only for the Company’s shareholders.

 

 

	 	Sincerely yours,
	 	 
	 	 
	 	Dvir Cohen, CEO
	 	Memic Innovative Surgery Ltd.

 

     

     

    

 

Memic
Innovative Surgery LTD

(The “Company”) 

 

Proxy

For a
Special General Meeting of the Shareholders of the Company 

 

Capitalized terms used
and not otherwise defined herein, shall have the respective meanings ascribed to them under the Notice of a Special General Meeting dated
[ ● ], 2021 (the “Meeting”), to which this Proxy was attached (the “Notice”) or under the Business Combination
Agreement (as defined below).

 

The undersigned (the “Shareholder”),
being the holder of [ ● ] Ordinary Shares, NIS 0.01 par value per share (“Company Ordinary Shares”) of
Memic Innovative Surgery Ltd. (the “Company”)[,] [ ● ] Series A Preferred Shares of the Company, NIS 0.01
par value per share (“Company Preferred A Shares”)[,] [ ● ] Series A-1 Preferred Shares of the Company,
NIS 0.01 par value per share (“Company Preferred A-1 Shares”)[,] [ ● ] Series B Preferred Shares of the
Company, NIS 0.01 par value per share (“Company Preferred B Shares”)[,] [ ● ] Series C-1 Preferred Shares
of the Company, NIS 0.01 par value per share (“Company Preferred C-1 Shares”) [,] [ ● ] Series C-2 Preferred
Shares of the Company, NIS 0.01 par value per share (“Company Preferred C-2 Shares”), [ ● ] Series D-1
Preferred Shares of the Company, NIS 0.01 par value per share (“Company Preferred D-1 Shares”), [ ● ]
Series D-2 Preferred Shares of the Company, NIS 0.01 par value per share (“Company Preferred D-2 Shares”), [
 ● ] Series D-3 Preferred Shares of the Company, NIS 0.01 par value per share (“Company Preferred D-3 Shares”),
and [ ● ] Series D-5 Preferred Shares of the Company, NIS 0.01 par value per share (“Company Preferred D-5 Shares”,
and, together with the Company Preferred A Shares, the Company Preferred A-1 Shares, the Company Preferred B Shares, the Company Preferred
C-1 Shares, the Company Preferred C-2 Shares, the Company Preferred D-1 Shares, the Company Preferred D-2 Shares, and the Company Preferred
D-3 Shares, the “Company Preferred Shares”), acting pursuant to Section 83(b) of the Israeli Companies Law,
5759-1999 and the Current Company Articles, does hereby irrevocably authorize _______________ to represent the Shareholder and vote all
of the [Company Ordinary Shares] [and] [Company Preferred Shares] held by the Shareholder, on behalf and in the name of the Shareholder,
at the Meeting, and at any postponements or adjournments thereof, as follows:

 

At the Meeting, the Shareholders will be asked
to approve the following resolutions:

 

“RESOLVED, to authorize and approve
the execution, delivery and performance of the Business Combination Agreement, dated as of August 12, 2021 (the “Business Combination
Agreement”), by and among the Company, MedTech Acquisition Corporation, a Delaware corporation (“SPAC”),
and Maestro Merger Sub, Inc., a Delaware corporation (“Merger Sub”), in the form attached hereto as Exhibit A,
and the Transactions, including the Reclassification, the Merger and issuance of the Price Adjustment Rights in the Reclassification,
as well as all of the Transaction Agreements to which the Company is a party and the termination of the Company’s Investors Rights
Agreement.”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

     

     

    

 

“RESOLVED, to approve and adopt the
Company’s 2021 Incentive Compensation Plan, in the form attached hereto as Exhibit B, as well as the Sub-Plan for
Israeli taxpayers in the form attached hereto as Exhibit C (collectively, the “Equity Plan”) and to authorize
the reserve for issuance under the Equity Plan a number of Company Ordinary Shares equal to 15% of the total number of issued and outstanding
Company Ordinary Shares on a fully diluted and as converted basis immediately following the Closing .”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

“RESOLVED, to authorize and approve,
contingent upon the Closing, the classification of the Company’s share capital by (A) converting all of the Company Preferred Shares
(including the Company Preferred Shares issued or issuable upon exercise of Company Warrants) into Company Ordinary Shares (with the voting
for such resolution (whether in person or by proxy) will constitute a written demand of all such holders of Company Preferred Shares)
in accordance with the conversion ratios determined pursuant to the Current Company Articles and (B) effect a share split of each Company
Ordinary Share, and each Company Ordinary Share underlying any Company Options and Company Warrants shall become [__] Company Ordinary
Shares par value ILS [__] each, such that following such classification , the Company’s authorized share capital shall be ILS [__]
divided into [__] Company Ordinary Shares, par value ILS [__] each.”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

“RESOLVED, to authorize and approve,
contingent upon the Closing, that the Price Adjustment Rights, the Merger Consideration, the Company Warrants and the Company Ordinary
Shares issuable upon exercise of any of the above, will be exempt and excluded from the definition of Additional Shares (as such term
is defined in the Current Company Articles).”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

“RESOLVED, to replace the Current
Company Articles in their entirety with the Company A&R Articles, in the form attached hereto as Exhibit D, contingent
upon the Closing.”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

“RESOLVED,
to approve the form of indemnification agreement, substantially in the form attached hereto as Exhibit E (the “Indemnification
Agreement”), and to authorize and approve the execution, delivery and performance of such Indemnification Agreement with each
director and officer of the Company, at present or in the future.”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

     

     

    

 

“RESOLVED, to approve, contingent
upon the Closing, that the following individuals be elected (or re-elected, as applicable) as members of the Board of Directors of the
Company (the “Board”), effective as of the Closing: [________], such that as of the Closing, the Board shall consist
of the following directors: [_______].”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

“RESOLVED, to approve and confirm
(A) the capitalization table attached hereto as Exhibit F, as being the complete, correct and accurate capitalization table
of the Company effective as of July 31, 2021, which reflects details of the Company’s share capital as of such time, and (B) the
shareholders register attached hereto as Exhibit G, as being the complete, correct and accurate register of shareholders
of the Company effective as of July 31, 2021, which reflects the details of all shares of the Company outstanding as of such time. To
approve any and all issuances of shares of the Company, any and all grants of warrants to purchase shares or other securities of the Company
(and, if applicable, the exercise thereof and the issuance of shares upon such exercise), any and all transfers of shares of the Company,
and any and all other actions previously made in, or with respect to, the share capital of the Company, in each case, which have been
consummated prior to the date hereof and that eventually resulted in the holdings of securities of the Company as specified in and contemplated
by Exhibit F and Exhibit G attached hereto (in each case, if and when made, and only to the extent not previously approved or ratified),
be ratified and approved in all respects effective as of the respective dates of such issuance, grant, exercise, transfer or other action,
as applicable, and that the issuance of the applicable shares of the Company upon the exercise of each warrant or other security or right
specified in Exhibit F attached hereto, if and when exercised in accordance with its respective terms, shall be ratified and approved
in all respects.”

 

	 	For*	 	Against*	 	Abstain*
	 	 	 	 	 	 

 

	 	 	 	 	 	 	 
	SHAREHOLDER*	 	SIGNATURE	 	NAME & TITLE	 	DATE
	(please PRINT name)	 	 	 	(for corporate entities)	 	 

 

*If this proxy represents shares held by more
than one person/entity, please list all such entities or provide separate proxies.

 

You are kindly requested to complete, date
and sign the enclosed proxy and deliver it to the Company at your earliest convenience, but in any event prior to the time appointed for
the meeting, by email to noam@memicmed.com.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]